Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.77 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.77 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.77 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.77 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.77 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.77 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2142888 | 0.93 | HDAC6 (1.00) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2227424 | 0.91 | HDAC6 (1.00) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2224925 | 0.88 | HDAC6 (1.00) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1232912 | 0.87 | HDAC6 (1.00) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL573254 | 0.87 | HDAC6 (1.00) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10050193 | 0.87 | HDAC6 (1.00) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2356695 | 0.87 | HDAC6 (1.00) | HDAC6 | |
| SCHEMBL2226872 | 0.86 | HDAC6 (1.00) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1232629 | 0.86 | HDAC6 (0.97) | HDAC6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2352985 | 0.86 | HDAC6 (1.00) | HDAC6HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105753739-A | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | 埃斯泰隆制药公司 | 2016-07-13 | — | — | CN | claimed |
| CN-102933558-A | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS | 2013-02-13 | — | — | CN | claimed |
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-12-08 | — | — | US | claimed |
| WO-2011091213-A2 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-07-28 | — | — | WO | claimed |
| US-11617750-B2 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-10648038-B2 | Biomarkers to identify patients that will respond to treatment and treating such patients | ACETYLON PHARMACEUTICALS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200030325-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200030325-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| EP-2839037-B1 | BIOMARKERS TO IDENTIFY PATIENTS THAT WILL RESPOND TO TREATMENT AND TREATING SUCH PATIENTS | ACETYLON PHARMACEUTICALS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20170327895-A1 | Biomarkers To Identify Patients That Will Respond To Treatment And Treating Such Patients | ACETYLON PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| WO-2013013113-A2 | HISTONE DEACETYLASE 6 SELECTIVE INHIBITORS FOR THE TREATMENT OF BONE DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013013113-A2 | HISTONE DEACETYLASE 6 SELECTIVE INHIBITORS FOR THE TREATMENT OF BONE DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20120190693-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2012-07-26 | — | — | US | disclosed |
| US-20120083504-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | ACETYLON PHARMACEUTICALS, INC. | 2012-04-05 | — | — | US | disclosed |
| US-8148526-B1 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | ACETYLON PHARMACEUTICALS (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011091213-A2 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011091213-A2 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300134-A1 | REVERSE AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC3 3/4885HDAC4 12/4885 |
| US-20200030325-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC3 3/4885HDAC4 12/4885 |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | HDAC1, HDAC6, HDAC9 | HDAC6 2/4885HDAC3 10/4885HDAC4 5/4885 |
| US-20120190693-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC3 3/4885HDAC4 12/4885 |
| US-20120083504-A1 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC3 3/4885HDAC4 12/4885 |
| US-11617750-B2 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC3 3/4885HDAC4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.